Sanford-Burnham Medical Research Institute has entered into a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to discover compounds for Alzheimer’s disease and major psychiatric disorders.
Florida Hospital, Sanford-Burnham Medical Research Institute and Takeda Pharmaceutical Company have signed a research agreement to discover and evaluate new therapeutic approaches to obesity.
Protein required for early stages of melanoma development can also predict melanoma outcome.
Deletion of key muscle protein inhibits exercise.
The $1 million gift will create the Art Brody Innovation Fund, which will support efforts to translate basic research discoveries into new medicines.
A protein called T-cadherin docks the fat hormone adiponectin to the heart, where it guards against stress-induced damage.
Sanford-Burnham researchers discover how the enzyme SHIP regulates B cell growth in mice, findings that could impact lymphoma drugs in development.
Sanford-Burnham researchers work to find new treatments for rare childhood diseases.
Scientists unravel the molecular link between damage-induced inflammation and muscle regeneration.
Powerful new software matches aberrant proteins with compounds that could fix them.
Research findings at Sanford-Burnham point to new ways to treat type 1 and type 2 diabetes.
The Sanford-Burnham Cancer Center's NCI core grant has been renewed for five years. The renewed grant includes a 21 percent increase in funding.
Sanford-Burnham co-founder Mrs. Lillian Fishman, 95, receives Distinguished Alumni Award from the University of Alberta.
Dr. Carl Ware has been appointed director of the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute.
Sanford-Burnham scientists uncover new clues to the molecular action of memantine, a drug used to treat Alzheimer’s disease, that show why side effects are rare.
Robert Wechsler-Reya, Ph.D., has been appointed professor and director of the Tumor Development Program at Sanford-Burnham Medical Research Institute. Dr. Wechsler-Reya will receive a $5.9 million Leadership Award from the California Institute for Regenerative Medicine, the first such award given by CIRM.
Sanford-Burnham researchers uncover new clues about the cause of brain cell death in neurodegenerative disorders such as Parkinson’s, Alzheimer’s, and Huntington’s diseases
New findings show that JNK, a protein already well known for other duties, also regulates the cell cycle.
Researchers uncover a mechanism that determines prostate cancer aggressiveness, providing new targets for diagnosis and treatment.
Sanford-Burnham researchers redirect a known pain reliever to trigger death pathways in cancer cells.
New model reveals the molecular basis of multiple hereditary exostoses and provides a tool to screen new treatments.
Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.
32nd Annual Sanford-Burnham Scientific Symposium provides wealth of information on microRNAs and RNAi.
Sanford-Burnham Medical Research Institute has promoted Kristiina Vuori, M.D., Ph.D., to President of the Institute. John C. Reed, M.D., Ph.D., Donald Bren Chief Executive Chair and former President, will continue as Chief Executive Officer.
Co-administered peptide directs medicines to tumors and deep into tumor tissue, increasing drug efficacy and reducing side effects
Studying Drosophila (fruit flies), an international team investigated 7061 genes and built a detailed map that shows how a portion of these genes contribute to heart function and disease. Importantly, the researchers identified many genes that had not previously been associated with heart disease.
Investigators at Sanford-Burnham Medical Research Institute led by Kristiina Vuori, M.D., Ph.D., have discovered that the natural compound sceptrin, which is found in marine sponges, reduces cancer cell motility (movement) and has very low toxicity.
An international team of investigators at Sanford-Burnham Medical Research Institute, Nijmegen Centre for Molecular Life Sciences and other organizations have discovered that TKS4, a protein implicated in cancer metastasis, also plays a significant role in Frank-Ter Haar syndrome (FTHS), a rare fatal disorder.
Investigators at Sanford-Burnham Medical Research Institute, the Karolinska Institutet, Beth Israel Deaconess Medical Center, Harvard Medical School and Université Libre de Bruxelles have demonstrated in mouse models that transplanted stems cells, when in direct contact with diseased neurons, send signals through specialized channels that rescue the neurons from death.
Investigators at Sanford-Burnham Medical Research Institute have discovered a new way the cell surface protein, CD44, helps specific T helper (Th1) cells develop immunologic memory.
Burnham Institute for Medical Research (Burnham) announced today that philanthropist T. Denny Sanford has pledged $50 million to support and further expand and accelerate the Institute’s leading-edge medical research. To honor Sanford, Burnham, has been renamed the Sanford-Burnham Medical Research Institute.
Investigators have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin H1N1.
Burnham Institute for Medical Research (Burnham) has appointed Executive Vice President Gary F. Raisl, Ed.D., to the position of Chief Financial Officer. In this role, Dr. Raisl will provide strategic direction and oversee the day-to-day financial operations of Burnham’s California and Florida campuses.
Researchers at Burnham Institute for Medical Research at University of California, Santa Barbara have identified a peptide (a chain of amino acids) that specifically recognizes and penetrates cancerous tumors but not normal tissues. The peptide was also shown to deliver diagnostic particles and medicines into the tumor.
Investigators at Burnham Institute for Medical Research UBC and UCSD have found that normal synaptic activity in nerve cells protects the brain from the misfolded proteins associated with Huntington’s disease.
Investigators at Burnham have identified a novel mouse gene that reduces the accumulation of two toxic proteins that are major players in Alzheimer’s disease: amyloid beta and tau. Amyloid beta is responsible for the plaques found in the brains of Alzheimer’s patients. Tau causes the tangles found within patients’ brain cells.
Burnham Institute for Medical Research announced today that Dr. Paul Laikind will join Burnham as Senior Vice President, Business Development and Chief Business Officer in November.
Burnham Institute for Medical Research has announced that five of its postdoctoral research fellows have been honored with Fishman Fund Awards to recognize their commitment to basic biomedical research. The awardees received $5,000 grants to be used to further their education and career development.
The University of Florida has reached a milestone in its efforts to build a research facility in Orlando at the emerging Lake Nona Medical City. A ceremony marking the official signing of the agreements was held immediately preceding the formal dedication of Burnham Institute for Medical Research’s Lake Nona campus.
Today, Burnham Institute for Medical Research (Burnham) officially dedicated its new 175,000-square-foot scientific facility and marked the opening of Orlando’s Medical City as a life science center.
Burnham Institute for Medical Research has appointed Michael R. Jackson, Ph.D., to the newly created position of Vice President for Drug Discovery and Development.
Investigators at Burnham Institute for Medical Research have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, researchers determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.
A new collaborative research program that will use the power of metabolomic profiling to help advance the concept of personalized medicine was announced September 17, 2009 by the Burnham Institute for Medical Research and the Sarah W. Stedman Nutrition and Metabolism Center at Duke University Medical Center.
Investigators at Burnham Institute for Medical Research, University of California, San Diego, The Scripps Research Institute, Genomics Institute of the Novartis Research Foundation and other institutions have constructed a complete model, including three dimensional protein structures, of the central metabolic network of the bacterium Thermotoga maritima (T. maritima).
Researchers at the Burnham Institute for Medical Research have discovered that reactive oxygen species, such as superoxide and hydrogen peroxide, play a key role in forming invadopodia, cellular protrusions implicated in cancer cell migration and tumor metastasis.
Investigators at Burnham Institute for Medical Research have found that the conserved protein d4eBP modulates cardiac aging in Drosophila (fruit flies). The team also found that d4eBP, which binds to the protein dEif4e, protects heart function against aging.
Dieter Wolf, M.D., and colleagues at Burnham Institute for Medical Research have illuminated how competition between proteins enhances combinatorial diversity during ubiquitination (the process that marks proteins for destruction).
Researchers at Burnham Institute for Medical Research, University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens. In addition, investigators discovered chemical compounds that can inhibit this enzyme and suppress the growth of pathogenic bacteria. These findings are essential to develop new broad-spectrum antibacterial agents to overcome multidrug resistance.
In its 33rd year, Burnham Institute for Medical Research has surpassed significant milestones in scientific achievement, research staffing and infrastructure development. As of July 1, 2009, the Institute exceeded 1,000 employees, including 74 full-time faculty and 800 scientific staff.
Investigators at Burnham Institute for Medical Research and the University of Connecticut Health Center have gained new understanding of the role hyaluronic acid (HA) plays in skeletal growth, chondrocyte maturation and joint formation in developing limbs. Significantly, these discoveries were made using a novel mouse model in which the production of HA is blocked in a tissue-specific manner.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right